Cite
HARVARD Citation
Craig, T. et al. (2023). Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401 (10382), pp. 1079-1090. [Online].